On August 8, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2024. The company highlighted the progress of its lead candidate, pemvidutide, in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). Altimmune presented promising data at medical conferences, showing pemvidutide's potential in weight loss and metabolic disease treatment. The company is preparing for an end-of-Phase 2 meeting with the FDA, expected in late Q3 2024, to discuss Phase 3 trial designs for obesity treatment. Financially, Altimmune reported $164.9 million in cash, cash equivalents, and short-term investments. Research and development expenses increased to $21.2 million, primarily due to pemvidutide development costs. General and administrative expenses rose to $5.6 million, attributed to increased stock compensation expenses. The company recorded a net loss of $24.6 million, or $0.35 per share, compared to a net loss of $16.1 million, or $0.32 per share, in the same period last year. The increase in net loss was primarily due to higher research and development spending.

On August 8, 2024, Altimmune, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2024. The company highlighted the progress of its lead candidate, pemvidutide, in treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). Altimmune presented promising data at medical conferences, showing pemvidutide's potential in weight loss and metabolic disease treatment. The company is preparing for an end-of-Phase 2 meeting with the FDA, expected in late Q3 2024, to discuss Phase 3 trial designs for obesity treatment. Financially, Altimmune reported $164.9 million in cash, cash equivalents, and short-term investments. Research and development expenses increased to $21.2 million, primarily due to pemvidutide development costs. General and administrative expenses rose to $5.6 million, attributed to increased stock compensation expenses. The company recorded a net loss of $24.6 million, or $0.35 per share, compared to a net loss of $16.1 million, or $0.32 per share, in the same period last year. The increase in net loss was primarily due to higher research and development spending.